Projektbeschreibung
Neuartige hochempfindliche Flüssigbiopsie für die Krebstherapie
Krebsbiomarker müssen während der Nachbehandlung und in der postoperativen Phase mit hoher Empfindlichkeit analysiert werden. Das EU-finanzierte Projekt BiopSense entwickelt eine neuartige Technologie, die eine sehr empfindliche Erkennung von Einzelnukleotid-Polymorphismen in den Proben und somit ein patientennahes Screening von Flüssigbiopsien gestattet. Diese Diagnoseplattform wird ein offenes System sein, das dem Design neuer diagnostischer Ziele Rechnung trägt. Die Technologie beruht auf einer patentierten Erfindung und wird Funktionen für automatische Probenvorbereitung und Lab-on-Chip-Design beinhalten. Zu den Projektzielen gehören die Verifizierung aller Plattformkomponenten sowie die Ermittlung der Empfindlichkeit und Genauigkeit der Chemie zur Bewertung im Vergleich zu einer konkurrierenden Massenspektrometrieplattform.
Ziel
Extremely high sensitivity is needed for the detection of cancer biomarkers during the follow-up of the treatment or post-operation period. We have identified a novel technology that enables very sensitive detection of single-nucleotide polymorphism from blood, enabling point-of-care screening of liquid biopsies. Our diagnostics platform will consist of new chemistry and device, and is an open system for designing new diagnostic targets. This will enable customized follow-up of the cancer medication in local hospitals and health care centers. The technology is based on our invention (US patent allowed) further developed in the ERC CoG project, but will have features for automated sample preparation and lab-on-chip design, which need to be verified and combined in the complete platform. For pre-commercialization of the technology, the sensitivity and accuracy of the chemistry will be determined and compared against competing mass spectrometric platform (UltraSEEK by Agena), upgrading our technology from phase TRL 4 to TRL 5. Patent shield of the technology is extended and options for transferring IPR from the University are clarified. Results are presented in investor convention and oncology conferences, and negotiations with investors and out-licensors are started. Three international biotech companies take part in the steering group. The technology allows business potential in device and kit production, but especially in international service business for personalised panel components and medical consultation. The expected price of the device and sample prep will be 30-40% cheaper than that of the closest competitor, but even better it allows flexible design of personalized diagnostic panels. The development for boosting the innovation to market will continue either through a spin-out supported by international investors, together with partnering companies, or through out-licensing.
Wissenschaftliches Gebiet
Programm/Programme
Thema/Themen
Finanzierungsplan
ERC-POC - Proof of Concept GrantGastgebende Einrichtung
40100 Jyvaskyla
Finnland